ARB-1467 (RNAi)

ARB-1467 (formerly TKM-HBV) comprises three RNAi triggers that target all four HBV transcripts, and has been shown in preclinical studies to reduce all viral antigen levels as well as cccDNA and HBV DNA.  ARB-1467 utilizes Arbutus’ proprietary lipid nanoparticle (LNP) platform, a clinically validated delivery technology which has been tested in hundreds of patients.

Phase II ARB-1467 Multi-dosing Clinical Trial

The ARB-1467 Phase II clinical trial is a multi-dose study in chronic HBV patients who are also receiving stable nucleot(s)ide analog therapy. The trial consists of three cohorts, each enrolling eight subjects; six receiving three monthly doses of ARB-1467, and two receiving placebo. The first two cohorts include hepatitis B e-antigen (HBeAg) negative patients, followed by a third cohort in HBeAg positive patients. Single dose ARB-1467 results for Cohorts 1 and 2 demonstrate significant reductions in serum hepatitis B surface antigen (HBsAg) levels. Importantly, multiple dose results from Cohort 1 show a step-wise, additive reduction in serum HBsAg. These multiple dose results are the first of their kind for an RNAi product candidate in patients with chronic HBV infection. This trial is currently ongoing. 

 

Visit www.clinicaltrials.gov for additional information on this study.

About Clinical Trials

 A clinical trial involves research using human volunteers (trial participants), and is intended to add to medical knowledge. Results can make a difference in the care of current and future patients by providing information about the benefits and risks of a potential drug. Visit www.ciscrp.org, the Center for Information and Study on Clinical Research Participation (CISCRP), an independent non-profit organization dedicated to educating and informing the public and patients about clinical research.